المؤلفون: Takayama Y, Sekizuka T, Matsui H, Adachi Y, Eda R, Nihonyanagi S, Wada T, Matsui M, Suzuki S, Takaso M, Kitasato H, Kuroda M, Hanaki H

المصدر: Infection and Drug Resistance, Vol Volume 13, Pp 561-566 (2020)

مصطلحات موضوعية: blandm-5, escherichia coli, sequence type 405, incfii, incfib, Infectious and parasitic diseases, RC109-216

الوصف: Yoko Takayama, 1, 2 Tsuyoshi Sekizuka, 3 Hidehito Matsui, 4 Yuzuru Adachi, 4 Ryotaro Eda, 5 Shin Nihonyanagi, 2 Tatsuhiko Wada, 2 Mari Matsui, 6 Satowa Suzuki, 6 Masashi Takaso, 7 Hidero Kitasato, 5 Makoto Kuroda, 3 Hideaki Hanaki 4 1Department of Infection Control and Infectious Diseases, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Kanagawa, Japan; 2Department of Infection Control and Prevention, Kitasato University Hospital, Kanagawa, Japan; 3Pathogen Genomics Center, National Institute of Infectious Diseases, Tokyo, Japan; 4Infection Control Research Center, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan; 5Department of Microbiology, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan; 6Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan; 7Department of Orthopaedic Surgery, Kitasato University School of Medicine, Kanagawa, JapanCorrespondence: Yoko Takayama 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa 252-0374, JapanTel/Fax +81-42-778-9119Email yoko@med.kitasato-u.ac.jpPurpose: New Delhi metallo-β-lactamase 5 (NDM-5) shows stronger resistance to carbapenems and broad-spectrum cephalosporins than NDM-1 because NDM-5 differs from NDM-1 by two amino acid substitutions. In this study, our aim was to characterize a NDM-5-producing Escherichia coli isolate KY1497 from a patient with urinary tract infection in Japan, who had no recent history of overseas travel.Patients and Methods: NDM-5-producing E. coli isolate KY1497 was detected in the urine sample of a patient hospitalized in a tertiary hospital in Japan. The complete genome sequence of isolate KY1497 was determined by short- and long-read sequencing with hybrid assembly, followed by multilocus sequence typing (MLST), core-genome phylogeny analysis, plasmid analysis, and transconjugation experiments.Results: KY1497 was classified as ST405 by MLST, and core-genome phylogeny exhibited the closest lineage to the clinical isolates in Nepal (IOMTU605) and Canada (FDAARGOS_448). KY1497 harbors blaNDM-5 in the IncFII-IncFIB(pB171) replicon plasmid (pKY1497_1, 123,767 base pairs). Plasmid analysis suggested that the cognate plasmids of pKY1497_1 have a minor plasmid background, rather than the globally disseminated IncX3 plasmid carrying blaNDM-5. Transconjugation analysis revealed that pKY1497_1 is transmissible to the recipient E. coli J53 strain.Conclusion: We characterized a novel Inc replicon plasmid (IncFII-IncFIB[pB171]) carrying blaNDM-5 and its host E. coli strain. NDMs are associated with a high risk of infection worldwide because of their antibiotic resistance and untreatable and hard-to-treat infections. Other patients in the hospital showed negative results for carbapenem-resistant Enterobacteriaceae. As NDM-producing strains are only sporadically detected in Japan, attention should be provided to the community prevalence of NDM-producing E. coli strains to prevent nosocomial infections.Keywords: blaNDM-5, Escherichia coli, sequence type 405, IncFII, IncFIB

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/characterization-of-the-incfii-incfibpb171-plasmid-carrying-blandm-5-i-peer-reviewed-article-IDRTest; https://doaj.org/toc/1178-6973Test

الوصول الحر: https://doaj.org/article/2acdd3ff6a1f42858027b603af2bce8fTest

المؤلفون: Horio, M., Forte, F., Sutter, D., Kim, M., Fatuzzo, C. G., Matt, C. E., Moser, S., Wada, T., Granata, V., Fittipaldi, R., Sassa, Y., Gatti, G., Rønnow, H. M., Hoesch, M., Kim, T. K., Jozwiak, C., Bostwick, A., Rotenberg, Eli, Matsuda, I., Georges, A., Sangiovanni, G., Vecchione, A., Cuoco, M., Chang, J.

المصدر: Commun. Phys. 6, 323 (2023)

مصطلحات موضوعية: Condensed Matter - Strongly Correlated Electrons

الوصف: Doped Mott insulators are the starting point for interesting physics such as high temperature superconductivity and quantum spin liquids. For multi-band Mott insulators, orbital selective ground states have been envisioned. However, orbital selective metals and Mott insulators have been difficult to realize experimentally. Here we demonstrate by photoemission spectroscopy how Ca$_2$RuO$_4$, upon alkali-metal surface doping, develops a single-band metal skin. Our dynamical mean field theory calculations reveal that homogeneous electron doping of Ca$_2$RuO$_4$ results in a multi-band metal. All together, our results provide compelling evidence for an orbital-selective Mott insulator breakdown, which is unachievable via simple electron doping. Supported by a cluster model and cluster perturbation theory calculations, we demonstrate a novel type of skin metal-insulator transition induced by surface dopants that orbital-selectively hybridize with the bulk Mott state and in turn produce coherent in-gap states.
Comment: A revised version of this manuscript will appear in Communications Physics

الوصول الحر: http://arxiv.org/abs/2310.13170Test

المؤلفون: Horio, M., Peiao, X., Miyamoto, M., Wada, T., Isomura, K., Osiecki, J., Thiagarajan, B., Polley, C. M., Tanaka, K., Kitamura, M., Horiba, K., Ozawa, K., Taniguchi, T., Fujita, M., Matsuda, I.

المصدر: Phys. Rev. B 108, 035105 (2023)

مصطلحات موضوعية: Condensed Matter - Strongly Correlated Electrons, Condensed Matter - Superconductivity

الوصف: We present an angle-resolved photoemission spectroscopy study of the single-layer T*-type structured cuprate SmLa$_{1-x}$Sr$_x$CuO$_4$ with unique five-fold pyramidal oxygen coordination. Upon varying oxygen content, T*-SmLa$_{1-x}$Sr$_x$CuO$_4$ evolved from a Mott-insulating to a metallic state where the Luttinger sum rule breaks down under the assumption of a large hole-like Fermi surface. This is in contrast with the known doping evolution of the structural isomer La$_{2-x}$Sr$_x$CuO$_4$ with six-fold octahedral coordination. In addition, quantitatively characterized Fermi surface suggests that the empirical $T_\mathrm{c}$ rule for octahedral oxygen-coordination systems does not apply to T*-SmLa$_{1-x}$Sr$_x$CuO$_4$. The present results highlight unique properties of the T*-type cuprates possibly rooted in its oxygen coordination, and necessitate thorough investigation with careful evaluation of disorder effects.
Comment: Accepted for publication in Phys. Rev. B

الوصول الحر: http://arxiv.org/abs/2306.13251Test

المؤلفون: Yagi S, Takashima A, Mitsugi M, Wada T, Hotchi J, Aihara K, Hara T, Ishida M, Fukuda D, Ise T, Yamaguchi K, Tobiume T, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Akaike M, Sata M

المصدر: Therapeutics and Clinical Risk Management, Vol 2015, Iss default, Pp 83-88 (2015)

مصطلحات موضوعية: Therapeutics. Pharmacology, RM1-950

الوصف: Shusuke Yagi,1 Akira Takashima,1 Minoru Mitsugi,2 Toshihiro Wada,2 Junko Hotchi,1 Ken-ichi Aihara,3 Tomoya Hara,1 Masayoshi Ishida,1 Daiju Fukuda,4 Takayuki Ise,1 Koji Yamaguchi,1 Takeshi Tobiume,1 Takashi Iwase,1 Hirotsugu Yamada,1 Takeshi Soeki,1 Tetsuzo Wakatsuki,1 Michio Shimabukuro,4 Masashi Akaike,5 Masataka Sata11Department of Cardiovascular Medicine, Graduate School of Health Biosciences, University of Tokushima, Tokushima, 2Department of Internal Medicine, Shikoku Central Hospital, Shikokuchuo, 3Department of Medicine and Bioregulatory Sciences, 4Department of Cardio-Diabetes Medicine, 5Department of Medical Education, Graduate School of Health Biosciences, University of Tokushima, Tokushima, JapanBackground: Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.Methods: We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.Results: The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.Conclusion: The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension.Keywords: blood pressure, combination tablet, uric acid, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol

وصف الملف: electronic resource

العلاقة: http://www.dovepress.com/effect-of-combination-tablets-containing-amlodipine-10-mg-and-irbesart-peer-reviewed-article-TCRMTest; https://doaj.org/toc/1178-203XTest

الوصول الحر: https://doaj.org/article/56fe1b54be224d74b6372169ebfa413fTest

المؤلفون: Scarfone, A. M., Matsuzoe, H., Wada, T.

المصدر: Phys. Lett. A 380, 2022-3028 (2016)

مصطلحات موضوعية: Condensed Matter - Statistical Mechanics, Mathematical Physics

الوصف: We show the robustness of the structure of Legendre transform in thermodynamics against the replacement of the standard linear average with the Kolmogorov-Nagumo nonlinear average to evaluate the expectation values of the macroscopic physical observables. The consequence of this statement is twofold: 1) the relationships between the expectation values and the corresponding Lagrange multipliers still hold in the present formalism; 2) the universality of the Gibbs equation as well as other thermodynamic relations are unaffected by the structure of the average used in the theory.
Comment: 15 pages, no figures, Elsart article style

الوصول الحر: http://arxiv.org/abs/2206.04414Test

المؤلفون: Tanaka, M., Takechi, M., Homma, A., Prochazka, A., Fukuda, M., Nishimura, D., Suzuki, T., Moriguchi, T., Ahn, D. S., Aimaganbetov, A., Amano, M., Arakawa, H., Bagchi, S., Behr, K. -H., Burtebayev, N., Chikaato, K., Du, H., Fujii, T., Fukuda, N., Geissel, H., Hori, T., Hoshino, S., Igosawa, R., Ikeda, A., Inabe, N., Inomata, K., Itahashi, K., Izumikawa, T., Kamioka, D., Kanda, N., Kato, I., Kenzhina, I., Korkulu, Z., Kuk, Y., Kusaka, K., Matsuta, K., Mihara, M., Miyata, E., Nagae, D., Nakamura, S., Nassurlla, M., Nishimuro, K., Nishizuka, K., Ohnishi, K., Ohtake, M., Ohtsubo, T., Omika, S., Ong, H. J., Ozawa, A., Sakurai, H., Scheidenberger, C., Shimizu, Y., Sugihara, T., Sumikama, T., Suzuki, H., Suzuki, S., Takeda, H., Tanaka, Y., Tanaka, Y. K., Tanihata, I., Wada, T., Wakayama, K., Yagi, S., Yamaguchi, T., Yanagihara, R., Yanagisawa, Y., Yoshida, K., Zholdybayev, T. K.

مصطلحات موضوعية: Nuclear Experiment, Nuclear Theory

الوصف: Charge-changing cross sections $\sigma_\mathrm{CC}$ for $^{42\textrm{--}51}$Ca on a carbon target at around 280~MeV/nucleon have been measured. The measured $\sigma_\mathrm{CC}$ values differ significantly from the previously developed calculations based on the Glauber model. However, through introduction of the charged-particle evaporation effect induced by the neutron-removal reaction in addition to the Glauber-model calculation, experimental $\sigma_\mathrm{CC}$ values on $^{12}$C at around 300~MeV/nucleon for nuclides from C to Fe isotopes are all reproduced with approximately 1\% accuracy. This proposed model systematically reproduces $\sigma_\mathrm{CC}$ data without phenomenological corrections, and can also explain experimental $\sigma_\mathrm{CC}$ values obtained in other energy regions.
Comment: 13 pages, 11 figures

الوصول الحر: http://arxiv.org/abs/2111.13340Test

المؤلفون: Kubota, Y., Tanaka, Yoshikazu, Togashi, T., Ebisu, T., Tamasaku, K., Osawa, H., Wada, T., Sugino, O., Matsuda, I., Yabashi, M.

المصدر: Applied Physics Letters 122, 092201 (2023)

مصطلحات موضوعية: Condensed Matter - Materials Science

الوصف: An ultrafast atomic motion of a photo-induced coherent phonon of bismuth at low temperatures was directly observed with time-resolved x-ray diffraction. A cryostat with a window that is transparent to both optical lasers and x-rays enabled versatile diffraction measurements in a wide temperature range including below 10 K. It is found that an atomic displacement in a fully symmetric A$_{\mathrm{1g}}$ phonon mode is suppressed at low temperatures. This result indicates the displacive excitation process is suppressed in the phonon generation with decreasing temperature.

الوصول الحر: http://arxiv.org/abs/2105.13146Test

المؤلفون: Liu, H., Li, Y., Zeng, Z., Cheng, H., Peng, C., Wada, T.

الوصف: Autonomous personal mobility vehicle (APMV) is a miniaturized autonomous vehicle designed for short-distance mobility to everyone. Due to its open design, APMV’s passengers are exposed to communications between the external human-machine interface (eHMI) on APMV and pedestrians. Therefore, effective eHMI designs for APMV need to consider potential impacts of APMV-pedestrian interactions on passengers’ subjective feelings. This study from the perspective of APMV passengers discussed three eHMI designs: (1) graphical user interface (GUI)-based eHMI with text message (eHMI-T), (2) multimodal user interface (MUI)-based eHMI with neutral voice (eHMI-NV), and (3) MUI-based eHMI with affective voice (eHMI-AV). In a riding field experiment (N = 24), eHMI-T made passengers feel awkward during the “silent time” when eHMI-T conveyed information exclusively to pedestrians, not passengers. MUI-based eHMIs with voice cues showed advantages, with eHMI-NV excelling in pragmatic quality and eHMI-AV in hedonic quality. Considering passengers’ personalities and genders in APMV eHMI design is also highlighted.

وصف الملف: text

العلاقة: https://eprints.whiterose.ac.uk/212980/1/Is%20Silent%20External%20Human%20Machine%20Interface%20%20eHMI%20%20Enough%20%20A%20Passenger-Centric%20Study%20on%20Effective%20eHMI%20for%20Autonomous%20Personal%20Mobility%20Vehicles%20in%20the.pdfTest; Liu, H. orcid.org/0000-0003-2195-3380 , Li, Y. orcid.org/0000-0001-7100-8040 , Zeng, Z. orcid.org/0000-0001-9188-2181 et al. (3 more authors) (2024) Is Silent External Human–Machine Interface (eHMI) Enough? A Passenger-Centric Study on Effective eHMI for Autonomous Personal Mobility Vehicles in the Field. International Journal of Human–Computer Interaction. ISSN 1044-7318

الإتاحة: https://eprints.whiterose.ac.uk/212980Test/
https://eprints.whiterose.ac.uk/212980/1/Is%20Silent%20External%20Human%20Machine%20Interface%20%20eHMI%20%20Enough%20%20A%20Passenger-Centric%20Study%20on%20Effective%20eHMI%20for%20Autonomous%20Personal%20Mobility%20Vehicles%20in%20the.pdfTest

المؤلفون: Koshino, A, Neuen, BL, Oshima, M, Toyama, T, Hara, A, Arnott, C, Neal, B, Jardine, M, Badve, SV, Mahaffey, KW, Pollock, C, Hansen, MK, Wada, T, Heerspink, HJL

المصدر: urn:ISSN:2468-0249 ; Kidney International Reports, 9, 2, 347-355

مصطلحات موضوعية: Clinical Research, Clinical Trials and Supportive Activities, Hematology, Kidney Disease, Prevention, Diabetes, 2 Aetiology, 2.1 Biological and endogenous factors, Metabolic and endocrine, Renal and urogenital, 3 Good Health and Well Being, SGLT2 inhibitor, anemia, biomarker, cardiovascular, kidney, mortality

الوصف: Introduction: Autoantibodies to erythropoietin receptor (anti-EPOR antibodies) have been identified in patients with various kidney diseases. However, data in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) is limited. We assessed the prevalence of anti-EPOR antibodies and their association with clinical outcomes in this population. Methods: The CREDENCE randomized patients with T2D and CKD to canagliflozin or placebo. Serum anti-EPOR antibodies, the exposure of interest, were measured using enzyme-linked immunosorbent assay. The primary outcome was doubling of serum creatinine, end-stage kidney disease, or death from kidney or cardiovascular (CV) causes. Secondary outcomes included CV and all-cause mortality. Multivariable Cox-regression models estimated associations between anti-EPOR antibodies and outcomes. The effects of canagliflozin on hemoglobin and hematocrit, stratified by the presence of anti-EPOR antibodies were assessed with a repeated measures mixed effects model. Results: Of 2600 participants with available biosamples, 191 (7.3%) were positive for anti-EPOR antibodies. Higher baseline anti-EPOR antibodies were associated with increased risk of primary outcome (hazard ratio [HR] per 1-SD increase = 1.12, 95% confidence interval [CI] = 1.01–1.24, P = 0.04), with CV death (HR = 1.27, 95% CI = 1.08–1.48, P < 0.01) and all-cause mortality (HR = 1.26, 95% CI = 1.11–1.43, P < 0.01). During follow-up, canagliflozin, compared to placebo, increased hemoglobin and hematocrit by 7.0 g/l (95% CI = 6.2–7.9) and 2.4% (2.2–2.7), respectively. These effects were consistent across patients with and without anti-EPOR antibodies (P-interaction = 0.24 and 0.36, respectively). Conclusion: In patients with T2D and CKD, anti-EPOR antibodies were associated with the composite kidney and CV outcome, as well as CV and all-cause mortality. Canagliflozin increased hemoglobin and hematocrit regardless of anti-EPOR antibodies.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/1959.4/unsworks_85167Test; https://unsworks.unsw.edu.au/bitstreams/fd397001-8203-4fc5-9aaf-f2b8206f7c44/downloadTest; https://doi.org/10.1016/j.ekir.2023.11.024Test

الإتاحة: https://doi.org/10.1016/j.ekir.2023.11.024Test
http://hdl.handle.net/1959.4/unsworks_85167Test
https://unsworks.unsw.edu.au/bitstreams/fd397001-8203-4fc5-9aaf-f2b8206f7c44/downloadTest

المؤلفون: Abat S., Abd Rahman R., Abdul Cader R., Abdul Hafidz M. I., Abdul Wahab M. Z., Abdullah N. K., Abdul-Samad T., Abe M., Abraham N., Acheampong S., Achiri P., Acosta J. A., Adeleke A., Adell V., Adewuyi-Dalton R., Adnan N., Africano A., Agharazii M., Aguilar F., Aguilera A., Ahmad M., Ahmad M. K., Ahmad N. A., Ahmad N. H., Ahmad N. I., Ahmad Miswan N., Ahmad Rosdi H., Ahmed I., Ahmed S., Aiello J., Aitken A., AitSadi R., Aker S., Akimoto S., Akinfolarin A., Akram S., Alberici F., Albert C., Aldrich L., Alegata M., Alexander L., Alfaress S., Alhadj Ali M., Ali A., Alicic R., Aliu A., Almaraz R., Almasarwah R., Almeida J., Aloisi A., Al-Rabadi L., Alscher D., Alvarez P., Al-Zeer B., Amat M., Ambrose C., Ammar H., An Y., Andriaccio L., Ansu K., Apostolidi A., Arai N., Araki H., Araki S., Arbi A., Arechiga O., Armstrong S., Arnold T., Aronoff S., Arriaga W., Arroyo J., Arteaga D., Asahara S., Asai A., Asai N., Asano S., Asawa M., Asmee M. F., Aucella F., Augustin M., Avery A., Awad A., Awang I. Y., Awazawa M., Axler A., Ayub W., Azhari Z., Baccaro R., Badin C., Bagwell B., Bahlmann-Kroll E., Bahtar A. Z., Baigent C., Bains D., Bajaj H., Baker R., Baldini E., Banas B., Banerjee D., Banno S., Bansal S., Barberi S., Barnes S., Barnini C., Barot C., Barrett K., Barrios R., Bartolomei Mecatti B., Barton I., Barton J., Basily W., Bavanandan S., Baxter A., Becker L., Beddhu S., Beige J., Beigh S., Bell S., Benck U., Beneat A., Bennett A., Bennett D., Benyon S., Berdeprado J., Bergler T., Bergner A., Berry M., Bevilacqua M., Bhairoo J., Bhandari S., Bhandary N., Bhatt A., Bhattarai M., Bhavsar M., Bian W., Bianchini F., Bianco S., Bilous R., Bilton J., Bilucaglia D., Bird C., Birudaraju D., Biscoveanu M., Blake C., Bleakley N., Bocchicchia K., Bodine S., Bodington R., Boedecker S., Bolduc M., Bolton S., Bond C., Boreky F., Boren K., Bouchi R., Bough L., Bovan D., Bowler C., Bowman L., Brar N., Braun C., Breach A., Breitenfeldt M., Brenner S., Brettschneider B., Brewer A., Brewer G., Brindle V., Brioni E., Brown C., Brown H., Brown L., Brown R., Brown S., Browne D., Bruce K., Brueckmann M., Brunskill N., Bryant M., Brzoska M., Bu Y., Buckman C., Budoff M., Bullen M., Burke A., Burnette S., Burston C., Busch M., Bushnell J., Butler S., Buttner C., Byrne C., Caamano A., Cadorna J., Cafiero C., Cagle M., Cai J., Calabrese K., Calvi C., Camilleri B., Camp S., Campbell D., Campbell R., Cao H., Capelli I., Caple M., Caplin B., Cardone A., Carle J., Carnall V., Caroppo M., Carr S., Carraro G., Carson M., Casares P., Castillo C., Castro C., Caudill B., Cejka V., Ceseri M., Cham L., Chamberlain A., Chambers J., Chan C. B. T., Chan J. Y. M., Chan Y. C., Chang E., Chant T., Chavagnon T., Chellamuthu P., Chen F., Chen J., Chen P., Chen T. M., Chen Y., Cheng C., Cheng H., Cheng M. C., Cherney D., Cheung A. K., Ching C. H., Chitalia N., Choksi R., Chukwu C., Chung K., Cianciolo G., Cipressa L., Clark S., Clarke H., Clarke R., Clarke S., Cleveland B., Cole E., Coles H., Condurache L., Connor A., Convery K., Cooper A., Cooper N., Cooper Z., Cooperman L., Cosgrove L., Coutts P., Cowley A., Craik R., Cui G., Cummins T., Dahl N., Dai H., Dajani L., D'Amelio A., Damian E., Damianik K., Danel L., Daniels C., Daniels T., Darbeau S., Darius H., Dasgupta T., Davies J., Davies L., Davis A., Davis J., Davis L., Dayanandan R., Dayi S., Dayrell R., De Nicola L., Debnath S., Deeb W., Degenhardt S., DeGoursey K., Delaney M., Deo R., DeRaad R., Derebail V., Dev D., Devaux M., Dhall P., Dhillon G., Dienes J., Dobre M., Doctolero E., Dodds V., Domingo D., Donaldson D., Donaldson P., Donhauser C., Donley V., Dorestin S., Dorey S., Doulton T., Draganova D., Draxlbauer K., Driver F., Du H., Dube F., Duck T., Dugal T., Dugas J., Dukka H., Dumann H., Durham W., Dursch M., Dykas R., Easow R., Eckrich E., Eden G., Edmerson E., Edwards H., Ee L. W., Eguchi J., Ehrl Y., Eichstadt K., Eid W., Eilerman B., Ejima Y., Eldon H., Ellam T., Elliott L., Ellison R., Emberson J., Epp R., Er A., Espino-Obrero M., Estcourt S., Estienne L., Evans G., Evans J., Evans S., Fabbri G., Fajardo-Moser M., Falcone C., Fani F., Faria-Shayler P., Farnia F., Farrugia D., Fechter M., Fellowes D., Feng F., Fernandez J., Ferraro P., Field A., Fikry S., Finch J., Finn H., Fioretto P., Fish R., Fleischer A., Fleming-Brown D., Fletcher L., Flora R., Foellinger C., Foligno N., Forest S., Forghani Z., Forsyth K., Fottrell-Gould D., Fox P., Frankel A., Fraser D., Frazier R., Frederick K., Freking N., French H., Froment A., Fuchs B., Fuessl L., Fujii H., Fujimoto A., Fujita A., Fujita K., Fujita Y., Fukagawa M., Fukao Y., Fukasawa A., Fuller T., Funayama T., Fung E., Furukawa M., Furukawa Y., Furusho M., Gabel S., Gaidu J., Gaiser S., Gallo K., Galloway C., Gambaro G., Gan C. C., Gangemi C., Gao M., Garcia K., Garcia M., Garofalo C., Garrity M., Garza A., Gasko S., Gavrila M., Gebeyehu B., Geddes A., Gentile G., George A., George J., Gesualdo L., Ghalli F., Ghanem A., Ghate T., Ghavampour S., Ghazi A., Gherman A., Giebeln-Hudnell U., Gill B., Gillham S., Girakossyan I., Girndt M., Giuffrida A., Glenwright M., Glider T., Gloria R., Glowski D., Goh B. L., Goh C. B., Gohda T., Goldenberg R., Goldfaden R., Goldsmith C., Golson B., Gonce V., Gong Q., Goodenough B., Goodwin N., Goonasekera M., Gordon A., Gordon J., Gore A., Goto H., Goto S., Gowen D., Grace A., Graham J., Grandaliano G., Gray M., Green J. B., Greene T., Greenwood G., Grewal B., Grifa R., Griffin D., Griffin S., Grimmer P., Grobovaite E., Grotjahn S., Guerini A., Guest C., Gunda S., Guo B., Guo Q., Haack S., Haase M., Haaser K., Habuki K., Hadley A., Hagan S., Hagge S., Haller H., Ham S., Hamal S., Hamamoto Y., Hamano N., Hamm M., Hanburry A., Haneda M., Hanf C., Hanif W., Hansen J., Hanson L., Hantel S., Haraguchi T., Harding E., Harding T., Hardy C., Hartner C., Harun Z., Harvill L., Hasan A., Hase H., Hasegawa F., Hasegawa T., Hashimoto A., Hashimoto C., Hashimoto M., Hashimoto S., Haskett S., Hauske S. J., Hawfield A., Hayami T., Hayashi M., Hayashi S., Haynes R., Hazara A., Healy C., Hecktman J., Heine G., Henderson H., Henschel R., Hepditch A., Herfurth K., Hernandez G., Hernandez Pena A., Hernandez-Cassis C., Herrington W. G., Herzog C., Hewins S., Hewitt D., Hichkad L., Higashi S., Higuchi C., Hill C., Hill L., Hill M., Himeno T., Hing A., Hirakawa Y., Hirata K., Hirota Y., Hisatake T., Hitchcock S., Hodakowski A., Hodge W., Hogan R., Hohenstatt U., Hohenstein B., Hooi L., Hope S., Hopley M., Horikawa S., Hosein D., Hosooka T., Hou L., Hou W., Howie L., Howson A., Hozak M., Htet Z., Hu X., Hu Y., Huang J., Huda N., Hudig L., Hudson A., Hugo C., Hull R., Hume L., Hundei W., Hunt N., Hunter A., Hurley S., Hurst A., Hutchinson C., Hyo T., Ibrahim F. H., Ibrahim S., Ihana N., Ikeda T., Imai A., Imamine R., Inamori A., Inazawa H., Ingell J., Inomata K., Inukai Y., Ioka M., Irtiza-Ali A., Isakova T., Isari W., Iselt M., Ishiguro A., Ishihara K., Ishikawa T., Ishimoto T., Ishizuka K., Ismail R., Itano S., Ito H., Ito K., Ito M., Ito Y., Iwagaitsu S., Iwaita Y., Iwakura T., Iwamoto M., Iwasa M., Iwasaki H., Iwasaki S., Izumi K., Izumi T., Jaafar S. M., Jackson C., Jackson Y., Jafari G., Jahangiriesmaili M., Jain N., Jansson K., Jasim H., Jeffers L., Jenkins A., Jesky M., Jesus-Silva J., Jeyarajah D., Jiang Y., Jiao X., Jimenez G., Jin B., Jin Q., Jochims J., Johns B., Johnson C., Johnson T., Jolly S., Jones L., Jones S., Jones T., Jones V., Joseph M., Joshi S., Judge P., Junejo N., Junus S., Kachele M., Kadowaki T., Kadoya H., Kaga H., Kai H., Kajio H., Kaluza-Schilling W., Kamaruzaman L., Kamarzarian A., Kamimura Y., Kamiya H., Kamundi C., Kan T., Kanaguchi Y., Kanazawa A., Kanda E., Kanegae S., Kaneko K., Kang H. Y., Kano T., Karim M., Karounos D., Karsan W., Kasagi R., Kashihara N., Katagiri H., Katanosaka A., Katayama A., Katayama M., Katiman E., Kato K., Kato M., Kato N., Kato S., Kato T., Kato Y., Katsuda Y., Katsuno T., Kaufeld J., Kavak Y., Kawai I., Kawai M., Kawase A., Kawashima S., Kazory A., Kearney J., Keith B., Kellett J., Kelley S., Kershaw M., Ketteler M., Khai Q., Khairullah Q., Khandwala H., Khoo K. K. L., Khwaja A., Kidokoro K., Kielstein J., Kihara M., Kimber C., Kimura S., Kinashi H., Kingston H., Kinomura M., Kinsella-Perks E., Kitagawa M., Kitajima M., Kitamura S., Kiyosue A., Kiyota M., Klauser F., Klausmann G., Kmietschak W., Knapp K., Knight C., Knoppe A., Knott C., Kobayashi M., Kobayashi R., Kobayashi T., Koch M., Kodama S., Kodani N., Kogure E., Koizumi M., Kojima H., Kojo T., Kolhe N., Komaba H., Komiya T., Komori H., Kon S. P., Kondo M., Kong W., Konishi M., Kono K., Koshino M., Kosugi T., Kothapalli B., Kozlowski T., Kraemer B., Kraemer-Guth A., Krappe J., Kraus D., Kriatselis C., Krieger C., Krish P., Kruger B., Ku Md Razi K. R., Kuan Y., Kubota S., Kuhn S., Kumar P., Kume S., Kummer I., Kumuji R., Kupper A., Kuramae T., Kurian L., Kuribayashi C., Kurien R., Kuroda E., Kurose T., Kutschat A., Kuwabara N., Kuwata H., La Manna G., Lacey M., Lafferty K., LaFleur P., Lai V., Laity E., Lambert A., Landray M. J., Langlois M., Latif F., Latore E., Laundy E., Laurienti D., Lawson A., Lay M., Leal I., Lee A. K., Lee J., Lee K. Q., Lee R., Lee S. A., Lee Y. Y., Lee-Barkey Y., Leonard N., Leoncini G., Leong C. M., Lerario S., Leslie A., Levin A., Lewington A., Li J., Li N., Li X., Li Y., Liberti L., Liberti M. E., Liew A., Liew Y. F., Lilavivat U., Lim S. K., Lim Y. S., Limon E., Lin H., Lioudaki E., Liu H., Liu J., Liu L., Liu Q., Liu W. J., Liu X., Liu Z., Loader D., Lochhead H., Loh C. L., Lorimer A., Loudermilk L., Loutan J., Low C. K., Low C. L., Low Y. M., Lozon Z., Lu Y., Lucci D., Ludwig U., Luker N., Lund D., Lustig R., Lyle S., Macdonald C., MacDougall I., Machicado R., MacLean D., Macleod P., Madera A., Madore F., Maeda K., Maegawa H., Maeno S., Mafham M., Magee J., Maggioni A. P., Mah D. Y., Mahabadi V., Maiguma M., Makita Y., Makos G., Manco L., Mangiacapra R., Manley J., Mann P., Mano S., Marcotte G., Maris J., Mark P., Markau S., Markovic M., Marshall C., Martin M., Martinez C., Martinez S., Martins G., Maruyama K., Maruyama S., Marx K., Maselli A., Masengu A., Maskill A., Masumoto S., Masutani K., Matsumoto M., Matsunaga T., Matsuoka N., Matsushita M., Matthews M., Matthias S., Matvienko E., Maurer M., Maxwell P., Mayne K. J., Mazlan N., Mazlan S. A., Mbuyisa A., McCafferty K., McCarroll F., McCarthy T., McClary-Wright C., McCray K., McDermott P., McDonald C., McDougall R., McHaffie E., McIntosh K., McKinley T., McLaughlin S., McLean N., McNeil L., Measor A., Meek J., Mehta A., Mehta R., Melandri M., Mene P., Meng T., Menne J., Merritt K., Merscher S., Meshykhi C., Messa P., Messinger L., Miftari N., Miller R., Miller Y., Miller-Hodges E., Minatoguchi M., Miners M., Minutolo R., Mita T., Miura Y., Miyaji M., Miyamoto S., Miyatsuka T., Miyazaki M., Miyazawa I., Mizumachi R., Mizuno M., Moffat S., Mohamad Nor F. S., Mohamad Zaini S. N., Mohamed Affandi F. A., Mohandas C., Mohd R., Mohd Fauzi N. A., Mohd Sharif N. H., Mohd Yusoff Y., Moist L., Moncada A., Montasser M., Moon A., Moran C., Morgan N., Moriarty J., Morig G., Morinaga H., Morino K., Morisaki T., Morishita Y., Morlok S., Morris A., Morris F., Mostafa S., Mostefai Y., Motegi M., Motherwell N., Motta D., Mottl A., Moys R., Mozaffari S., Muir J., Mulhern J., Mulligan S., Munakata Y., Murakami C., Murakoshi M., Murawska A., Murphy K., Murphy L., Murray S., Murtagh H., Musa M. A., Mushahar L., Mustafa R., Mustafar R., Muto M., Nadar E., Nagano R., Nagasawa T., Nagashima E., Nagasu H., Nagelberg S., Nair H., Nakagawa Y., Nakahara M., Nakamura J., Nakamura R., Nakamura T., Nakaoka M., Nakashima E., Nakata J., Nakata M., Nakatani S., Nakatsuka A., Nakayama Y., Nakhoul G., Nangaku M., Naverrete G., Navivala A., Nazeer I., Negrea L., Nethaji C., Newman E., Ng S. Y. A., Ng T. J., Ngu L. L. S., Nimbkar T., Nishi H., Nishi M., Nishi S., Nishida Y., Nishiyama A., Niu J., Niu P., Nobili G., Nohara N., Nojima I., Nolan J., Nosseir H., Nozawa M., Nunn M., Nunokawa S., Oda M., Oe M., Oe Y., Ogane K., Ogawa W., Ogihara T., Oguchi G., Ohsugi M., Oishi K., Okada Y., Okajyo J., Okamoto S., Okamura K., Olufuwa O., Oluyombo R., Omata A., Omori Y., Ong L. M., Ong Y. C., Onyema J., Oomatia A., Oommen A., Oremus R., Orimo Y., Ortalda V., Osaki Y., Osawa Y., Osmond Foster J., O'Sullivan A., Otani T., Othman N., Otomo S., O'Toole J., Owen L., Ozawa T., Padiyar A., Page N., Pajak S., Paliege A., Pandey A., Pandey R., Pariani H., Park J., Parrigon M., Passauer J., Patecki M., Patel M., Patel R., Patel T., Patel Z., Paul R., Paulsen L., Pavone L., Peixoto A., Peji J., Peng B. C., Peng K., Pennino L., Pereira E., Perez E., Pergola P., Pesce F., Pessolano G., Petchey W., Petr E. J., Pfab T., Phelan P., Phillips R., Phillips T., Phipps M., Piccinni G., Pickett T., Pickworth S., Piemontese M., Pinto D., Piper J., Plummer-Morgan J., Poehler D., Polese L., Poma V., Pontremoli R., Postal A., Potz C., Power A., Pradhan N., Pradhan R., Preiss D., Preiss E., Preston K., Prib N., Price L., Provenzano C., Pugay C., Pulido R., Putz F., Qiao Y., Quartagno R., Quashie-Akponeware M., Rabara R., Rabasa-Lhoret R., Radhakrishnan D., Radley M., Raff R., Raguwaran S., Rahbari-Oskoui F., Rahman M., Rahmat K., Ramadoss S., Ramanaidu S., Ramasamy S., Ramli R., Ramli S., Ramsey T., Rankin A., Rashidi A., Raymond L., Razali W. A. F. A., Read K., Reiner H., Reisler A., Reith C., Renner J., Rettenmaier B., Richmond L., Rijos D., Rivera R., Rivers V., Robinson H., Rocco M., Rodriguez-Bachiller I., Rodriquez R., Roesch C., Roesch J., Rogers J., Rohnstock M., Rolfsmeier S., Roman M., Romo A., Rosati A., Rosenberg S., Ross T., Rossello X., Roura M., Roussel M., Rovner S., Roy S., Rucker S., Rump L., Ruocco M., Ruse S., Russo F., Russo M., Ryder M., Sabarai A., Sacca C., Sachson R., Sadler E., Safiee N. S., Sahani M., Saillant A., Saini J., Saito C., Saito S., Sakaguchi K., Sakai M., Salim H., Salviani C., Sammons E., Sampson A., Samson F., Sandercock P., Sanguila S., Santorelli G., Santoro D., Sarabu N., Saram T., Sardell R., Sasajima H., Sasaki T., Satko S., Sato A., Sato D., Sato H., Sato J., Sato T., Sato Y., Satoh M., Sawada K., Schanz M., Scheidemantel F., Schemmelmann M., Schettler E., Schettler V., Schlieper G. R., Schmidt C., Schmidt G., Schmidt U., Schmidt-Gurtler H., Schmude M., Schneider A., Schneider I., Schneider-Danwitz C., Schomig M., Schramm T., Schreiber A., Schricker S., Schroppel B., Schulte-Kemna L., Schulz E., Schumacher B., Schuster A., Schwab A., Scolari F., Scott A., Seeger W., Segal M., Seifert L., Seifert M., Sekiya M., Sellars R., Seman M. R., Shah S., Shainberg L., Shanmuganathan M., Shao F., Sharma K., Sharpe C., Sheikh-Ali M., Sheldon J., Shenton C., Shepherd A., Shepperd M., Sheridan R., Sheriff Z., Shibata Y., Shigehara T., Shikata K., Shimamura K., Shimano H., Shimizu Y., Shimoda H., Shin K., Shivashankar G., Shojima N., Silva R., Sim C. S. B., Simmons K., Sinha S., Sitter T., Sivanandam S., Skipper M., Sloan K., Sloan L., Smith R., Smyth J., Sobande T., Sobata M., Somalanka S., Song X., Sonntag F., Sood B., Sor S. Y., Soufer J., Sparks H., Spatoliatore G., Spinola T., Squyres S., Srivastava A., Stanfield J., Staplin N., Staylor K., Steele A., Steen O., Steffl D., Stegbauer J., Stellbrink C., Stellbrink E., Stevens W., Stevenson A., Stewart-Ray V., Stickley J., Stoffler D., Stratmann B., Streitenberger S., Strutz F., Stubbs J., Stumpf J., Suazo N., Suchinda P., Suckling R., Sudin A., Sugamori K., Sugawara H., Sugawara K., Sugimoto D., Sugiyama H., Sugiyama T., Sullivan M., Sumi M., Suresh N., Sutton D., Suzuki H., Suzuki R., Suzuki Y., Swanson E., Swift P., Syed S., Szerlip H., Taal M., Taddeo M., Tailor C., Tajima K., Takagi M., Takahashi K., Takahashi M., Takahashi T., Takahira E., Takai T., Takaoka M., Takeoka J., Takesada A., Takezawa M., Talbot M., Taliercio J., Talsania T., Tamori Y., Tamura R., Tamura Y., Tan C. H. H., Tan E. Z. Z., Tanabe A., Tanabe K., Tanaka A., Tanaka N., Tang S., Tang Z., Tanigaki K., Tarlac M., Tatsuzawa A., Tay J. F., Tay L. L., Taylor J., Taylor K., Te A., Tenbusch L., Teng K. S., Terakawa A., Terry J., Tham Z. D., Tholl S., Thomas G., Thong K. M., Tietjen D., Timadjer A., Tindall H., Tipper S., Tobin K., Toda N., Tokuyama A., Tolibas M., Tomita A., Tomita T., Tomlinson J., Tonks L., Topf J., Topping S., Torp A., Torres A., Totaro F., Toth P., Toyonaga Y., Tripodi F., Trivedi K., Tropman E., Tschope D., Tse J., Tsuji K., Tsunekawa S., Tsunoda R., Tucky B., Tufail S., Tuffaha A., Turan E., Turner H., Turner J., Turner M., Tuttle K. R., Tye Y. L., Tyler A., Tyler J., Uchi H., Uchida H., Uchida T., Udagawa T., Ueda S., Ueda Y., Ueki K., Ugni S., Ugwu E., Umeno R., Unekawa C., Uozumi K., Urquia K., Valleteau A., Valletta C., van Erp R., Vanhoy C., Varad V., Varma R., Varughese A., Vasquez P., Vasseur A., Veelken R., Velagapudi C., Verdel K., Vettoretti S., Vezzoli G., Vielhauer V., Viera R., Vilar E., Villaruel S., Vinall L., Vinathan J., Visnjic M., Voigt E., von-Eynatten M., Vourvou M., Wada J., Wada T., Wada Y., Wakayama K., Wakita Y., Wallendszus K., Walters T., Wan Mohamad W. H., Wang L., Wang W., Wang X., Wang Y., Wanner C., Wanninayake S., Watada H., Watanabe K., Watanabe M., Waterfall H., Watkins D., Watson S., Weaving L., Weber B., Webley Y., Webster A., Webster M., Weetman M., Wei W., Weihprecht H., Weiland L., Weinmann-Menke J., Weinreich T., Wendt R., Weng Y., Whalen M., Whalley G., Wheatley R., Wheeler A., Wheeler J., Whelton P., White K., Whitmore B., Whittaker S., Wiebel J., Wiley J., Wilkinson L., Willett M., Williams A., Williams E., Williams K., Williams T., Wilson A., Wilson P., Wincott L., Wines E., Winkelmann B., Winkler M., Winter-Goodwin B., Witczak J., Wittes J., Wittmann M., Wolf G., Wolf L., Wolfling R., Wong C., Wong E., Wong H. S., Wong L. W., Wong Y. H., Wonnacott A., Wood A., Wood L., Woodhouse H., Wooding N., Woodman A., Wren K., Wu J., Wu P., Xia S., Xiao H., Xiao X., Xie Y., Xu C., Xu Y., Xue H., Yahaya H., Yalamanchili H., Yamada A., Yamada N., Yamagata K., Yamaguchi M., Yamaji Y., Yamamoto A., Yamamoto S., Yamamoto T., Yamanaka A., Yamano T., Yamanouchi Y., Yamasaki N., Yamasaki Y., Yamashita C., Yamauchi T., Yan Q., Yanagisawa E., Yang F., Yang L., Yano S., Yao S., Yao Y., Yarlagadda S., Yasuda Y., Yiu V., Yokoyama T., Yoshida S., Yoshidome E., Yoshikawa H., Young A., Young T., Yousif V., Yu H., Yu Y., Yuasa K., Yusof N., Zalunardo N., Zander B., Zani R., Zappulo F., Zayed M., Zemann B., Zettergren P., Zhang H., Zhang L., Zhang N., Zhang X., Zhao J., Zhao L., Zhao S., Zhao Z., Zhong H., Zhou N., Zhou S., Zhu D., Zhu L., Zhu S., Zietz M., Zippo M., Zirino F., Zulkipli F. H., Judge P. K., Emberson J. R., Roddick A. J., Liu Z. H., Hooi L. S., Steubl D., Massey D.

المساهمون: Abat S., Abd Rahman R., Abdul Cader R., Abdul Hafidz M.I., Abdul Wahab M.Z., Abdullah N.K., Abdul-Samad T., Abe M., Abraham N., Acheampong S., Achiri P., Acosta J.A., Adeleke A., Adell V., Adewuyi-Dalton R., Adnan N., Africano A., Agharazii M., Aguilar F., Aguilera A., Ahmad M., Ahmad M.K., Ahmad N.A., Ahmad N.H., Ahmad N.I., Ahmad Miswan N., Ahmad Rosdi H., Ahmed I., Ahmed S., Aiello J., Aitken A., AitSadi R., Aker S., Akimoto S., Akinfolarin A., Akram S., Alberici F., Albert C., Aldrich L., Alegata M., Alexander L., Alfaress S., Alhadj Ali M., Ali A., Alicic R., Aliu A., Almaraz R., Almasarwah R., Almeida J., Aloisi A., Al-Rabadi L., Alscher D., Alvarez P., Al-Zeer B., Amat M., Ambrose C., Ammar H., An Y., Andriaccio L., Ansu K., Apostolidi A., Arai N., Araki H., Araki S., Arbi A., Arechiga O., Armstrong S., Arnold T., Aronoff S., Arriaga W., Arroyo J., Arteaga D., Asahara S., Asai A., Asai N., Asano S., Asawa M., Asmee M.F., Aucella F., Augustin M., Avery A., Awad A., Awang I.Y., Awazawa M., Axler A., Ayub W., Azhari Z., Baccaro R., Badin C., Bagwell B., Bahlmann-Kroll E., Bahtar A.Z., Baigent C., Bains D., Bajaj H., Baker R., Baldini E., Banas B., Banerjee D., Banno S.

الوصف: Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38061372; info:eu-repo/semantics/altIdentifier/wos/WOS:001148079800001; volume:12; issue:1; firstpage:51; lastpage:60; numberofpages:10; journal:THE LANCET DIABETES & ENDOCRINOLOGY; https://hdl.handle.net/11585/963286Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85179107702; https://www.thelancet.com/journals/landia/article/PIIS2213-8587Test(23)00322-4/fulltext

الإتاحة: https://doi.org/10.1016/S2213-8587Test(23)00322-4
https://hdl.handle.net/11585/963286Test
https://www.thelancet.com/journals/landia/article/PIIS2213-8587Test(23)00322-4/fulltext